News Highlights

May 11, 2012
Concert Pharmaceuticals Presents Clinical Results Demonstrating CTP-499 is Well-Tolerated in Patients with Stage 3 Chronic Kidney Disease; Results Presented at National Kidney Foundation 2012 Spring Clinical Meetings

March 5, 2012
Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-499 for the Treatment of Diabetic Nephropathy

March 5, 2012
Concert Pharmaceuticals and Fast Forward Announce Collaboration to Advance Novel Treatment for Spasticity and Pain in Multiple Sclerosis

February 29, 2012
Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-Modified Dextromethorphan for Disorders of the Nervous System

more...

Welcome to Concert

Concert uses deuterium-based chemistry to create and develop highly differentiated new medicines by leveraging decades of pharmaceutical and clinical experience to reduce time, risk and expense.

Concert in the news... a selection of news stories featuring Concert.

Healthcare Global Magazine Concert Pharmaceuticals Changes the Industry with Deuterium

Upcoming Events

Concert will participate on a panel at the BIO International Convention on June 20, 2012 in Boston

Business Development/Strategic Partnering

Concert business development will participate at Argyle Executive Forum on June 14, 2012 in New York